FIXX News and Press, Homology Medicines Inc. From 04/29/20

BEDFORD, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today upcoming presentations demonstrating the broad applicability of its in vivo gene therapy and nuclease-free gene editing platform across multiple disea...

Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...

- Data Package Supported Initiation of Ongoing pheNIX Clinical Trial for  Adults with PKU - BEDFORD, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of preclinical data th...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Homology Medicines (NASDAQ: FIXX ): Q4 GAAP EPS of -$0.55 beats by $0.13 . Revenue of $0.56M (-53.3% Y/Y) beats by $0.11M . Press Release More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news,

- Announced Encouraging Initial Clinical Data From the Phase 1/2 pheNIX PKU Gene Therapy Trial and Expects to Select Dose for Randomized, Concurrently Controlled Expansion Part  Mid-Year 2020 - - Executed 2,000-Liter Bioreactor Scale in Internal Facility with Commercial Manu...

BEDFORD, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following investor and scientific conferences: BTIG Targeted Therapeutics Conference at The St. Regis New York ...

- Data Demonstrate AAVHSCs Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier, Produced Normal Levels of Human Protein and Reduced Key Biochemical Markers of Disease in Preclinical Models - BEDFORD, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX),...

Dosing is underway in a Phase 1 clinical trial evaluating Rubius Therapeutics' ( RUBY -4.5% ) lead candidate RTX-134, an allogeneic off-the-shelf cell therapy, for the potential treatment of phenylketonuria (PKU), a rare inborn error of metabolism characterized by the buildup of the am...

Genetic medicines and cellular therapies have an enormous potential to treat, and possibly cure, currently untreatable diseases. Nonetheless, it's important for investors to remember that "simpler" treatment options won't become obsolete just because gene therapy, gene editing, and immunotherapy...